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Background: Wild ducks play an important role in the evolution of avian influenza viruses (AIVs). Domestic ducks in
China are known to carry and spread H9N2 AIVs that are thought to have contributed internal genes for the recent
outbreak of zoonotic H7N9 virus. In order to protect animal and public health, an effective vaccine is urgently needed
to block and prevent the spread of H9N2 virus in ducks. We developed an inactivated H9N2 vaccine (with adjuvant
Montanide ISA 70VG) based on an endemic H9N2 AIV and evaluated this vaccine in ducks.
Findings: The results showed that the inactivated H9N2 vaccine was able to induce a strong and fast humoral immune
response in vaccinated ducks. The hemagglutination inhibition titer in the sera increased fast, and reached its peak of 12.3
log2 at 5 weeks post-vaccination in immunized birds and remained at a high level for at least 37 weeks post-vaccination.
Moreover, viral shedding was completely blocked in vaccinated ducks after challenge with a homologous H9N2 AIV at
both 3 and 37 weeks post-vaccination.
Conclusions: The results of this study indicate that the inactivated H9N2 vaccine induces high and prolonged immune
response in vaccinated ducks and are efficacious in protecting ducks from H9N2 infection.Findings
There is an increasing public health concern regarding
the spread of H9N2 avian influenza viruses (AIVs) due
to its potential for host-range extension, virulence en-
hancement, and providing internal genes, resulting in
reassortment with other subtype influenza viruses through
horizontal transmission [1–6]. The latter was exemplified
by the zoonotic H7N9 virus that has caused outbreaks in
China [6]. As a prominent reservoir of AIVs, ducks play an
important role in the evolution, and spread of many sub-
types of AIVs [7]. It was recently found that H9N2 AIVs
were prevalent in domestic ducks from farms and live bird
markets in China [8]; however, infections of low-pathogenic
AIVs were generally overlooked, owing to the lack of clin-
ical symptoms [6, 8]. Therefore, prevention of viral shed-
ding of H9N2 AIVs in ducks is a challenging but crucial
and important step in protecting animal and public health.* Correspondence: lizejun@shvri.ac.cn
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most effective ways to prevent and control influenza in
chickens [9]. However, research on vaccines against
H9N2 AIVs in ducks is scarce. In this study, we have
developed an inactivated H9N2 vaccine (with adjuvant
Montanide ISA 70VG) based on an H9N2 A/duck/
Shanghai/441/2009 (SH441) virus that is very closed to
currently endemic H9N2 virus in China and its efficacy
was evaluated in ducks.
Our preliminary studies showed that the H9N2 AIVs
could not infect and replicate in ducks efficiently by an
intranasal infection route. Similar results were observed
for H10 subtype viruses that replicated poorly in ducks
by an intranasal inoculation; however, they replicated-
efficiently by the intravenous infection [10]. Therefore,
we infected ducks intravenously in order to develop an
H9N2 challenge model. Five H9N2 duck isolates (SH96,
SH441, SH480, SH1494 and SH1753) were selected to
infect groups of 9 week-old outbred sheldducks (n = 5).
Each duck was intravenously inoculated with 106 of
50 % egg infective dose (EID50) of each virus. Oropha-
ryngeal and cloacal swabs were collected each day from
1 to 5 post-inoculation (dpi) for detecting virus shedding.s distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
SH441 SH1753
Fig. 1 Viral titer of oropharyngeal swabs collected from ducks infected with different H9N2 viruses. Ducks were intravenously inoculated with 106
EID50 of SH441 or SH1753. The virus titers (EID50) were determined for oropharyngeal swabs collected from infected ducks. The PBS-inoculated group
was used as controls. The horizon line represents the mean value
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gen free(SPF) embryonated chicken eggs and passaged
twice to isolate virus. The results showed that no virus
was detected in any cloacal swabs collected from all ducks
inoculated with each virus. oropharyngeal swabs collected
from ducks infected with SH96, SH480, or SH1494 strains
were negative for virus isolation at 1–5 dpi; while the
SH1753 virus was isolated from the oropharyngeal swabs
collected from two of five infected ducks at 3 dpi, not at
other time points [Fig. 1]. All oropharyngeal swabs col-
lected from 5 ducks infected with the SH441 virus were
positive for virus isolation at 1, 2 and 3 dpi, and the viral
titers were approximately 1.5 log10 EID50 per ml [Fig. 1].
All these results indicate that the H9N2 AIVs do not repli-
cate efficiently in ducks, and are consistent with previous
studies in ducks and chickens [11, 12]. Wang et al. re-
ported that the virus could be detected in the oropharyn-
geal swabs collected from the ducks that were intranasallyWeeks post-vac

















Fig. 2 Antibody dynamics of vaccinated ducks. Six-week-old ducks were in
(H9N2, SH441) The mean HI titers for sera collected weekly or bi-weekly duinfected with 107 EID50 of different H9N2 AIVs at 2 and 3
dpi [11]. Only a small proportion of inoculated chickens
shed detectable viruses found in the cloacal swabs after in-
tranasal infection with chicken origin H9N2 viruses [12].
Moreover, 3 week-old ducks were intravenously inocu-
lated with the above H9N2 viruses in our preliminary
experiment (data not shown) and similar results were ob-
tained as those using 9 week-old ducks in this study. This
suggests that different ages of ducks show similar suscepti-
bility to the H9N2 virus infections. Taken together, our
results indicate that ducks intravenously infected with the
SH441 virus can be used as a model to evaluate efficacy of
the developed H9N2 inactivated vaccine.
To assess the protective efficacy of the developed
H9N2 inactivated vaccine, ducks were intramuscularly
vaccinated with 0.3 ml of the inactivated vaccine, and
then intravenously challenged with 106 EID50 of a homolo-
gous H9N2 (SH441) virus after 3 weeks post-vaccination.cination
23 25 27 29 31 33 37
Inactivated vaccine
Negative control
tramuscularly immunized with the developed inactivated vaccine
ring 37 weeks post-inoculation are shown
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in ducks, and the HI titers against the H9N2 virus were
over 11.0 log2 after 3 weeks post-vaccination (Table 1). All
five vaccinated ducks were protected against the SH441
challenge when compared to control unvaccinated birds,
evidenced by the fact that no virus was recovered from the
oropharyngeal swabs collected from the vaccinated birds,
while virus was detected in all oropharyngeal swabs
collected from the control birds.
To determine dynamics of the HI antibody in immu-
nized birds, serum was collected from H9N2-vaccinated
ducks weekly or bi-weekly and tested by the HI assay.
The mean HI titer increased very fast, and reached its
peak at 12.3 log2 at 5 weeks post-vaccination [Fig. 2].
The HI titers were still detectable after 37 weeks post-
vaccination with a higher level. In contrast, previous stud-
ies with a recombinant H5 vector vaccine showed that the
highest HI titer against H5 virus only reached 7 log2 [13]
and lasted for 12 weeks after post-vaccination [14]. To de-
termine whether ducks can be protected after 37 weeks
post-vaccination, a group of vaccinated ducks were chal-
lenged with a homologous H9N2 virus (Table 1). The re-
sults showed that the vaccine completely protected ducks
from oropharyngeal viral shedding after challenge with
the H9N2 virus even after 37 weeks post-vaccination.
In summary, our results demonstrate that the developed
H9N2 inactivated vaccine is able to induce protective
immune responses and is efficacious in ducks, suggesting
that this vaccine could be used in poultry industry to pre-
vent and control H9N2 influenza in ducks.
Viruses and ducks
Five H9N2 virus isolates A/duck/Shanghai/96/2009 (SH96),
A/duck/Shanghai/441/2009 (SH441), A/duck/Shanghai/
480/2009 (SH480), A/duck/Shanghai/1494/2009 (SH1494),
and A/duck/Shanghai/1753/2009 (SH1753) were used in
this study. Each virus was amplified in 9–11-day-old SPF
embryonated chicken eggs, and virus titer (EID50) was de-
termined in SPF embryonated chicken eggs and calculated
by the Reed and Muench method based on the HA assay
of allantoic fluid of eggs inoculated with 10-fold serial dilu-
tions of viruses [15]. Ducks (a local outbred strain of shel-
ducks) used in this study, were confirmed to be free of any
AIV infection. Before challenge, sera and swab samplesTable 1 Evaluation of vaccine efficacy for protection of ducks from






dpi, days post-infection, PBS, phosphate-buffered saline (negative control)were collected from each bird for the HI assay against H9
and virus isolation as described previously [16], all the
results were negative. Each group of ducks were housed in
a separated isolator.
H9N2 viral infection
To test the infectivity of H9N2 viruses in ducks, groups
of 9 week-old ducks were intravenously inoculated (n = 5)
with 106 EID50 of each H9N2 virus in a volume of 100 μL.
Negative control ducks were inoculated with same volume
of phosphate-buffered saline (PBS). Oropharyngeal and
cloacal swabs were collected daily from 1 to 5 dpi.
Oropharyngeal and cloacal swabs were incubated and
treated with antibiotics to reduce bacterial contamin-
ation. The serial diluents of supernatants of oropha-
ryngeal and cloacal swabs were inoculated into SPF
embryonated chicken eggs to determine the virus
titer (EID50) that was calculated by the Reed and
Muench method.
Vaccine development
The SH441 strain was selected for use to produce an
inactivated vaccine because i) it can grow a very high
titer (hemagglutination titer 12log2) and ii) it is closed
related genetically and antigenically to currently endemic
H9N2 viruses. To produce the inactivated vaccine, the
amplified virus was inactivated by β-propiolactone
(Sigma-Aldrich,St. Louis, MO, USA), then mixed with
an adjuvant Montanide ISA 70VG (Seppic, Paris, France)
at a ratio of 3:7 (V/V) according to the manufacturer’s
instruction.
Hemagglutination inhibition (HI) assay
Blood samples were collected weekly or bi-weekly until
37 weeks post-vaccination. Sera were isolated and HI titers
were determined by HI assays as described previously [17].
Duck vaccination and virus challenge with SH441
Six-week-old ducks were intramuscularly inoculated
with 0.3 ml of the inactivated vaccine in the vaccination
group (n = 15) or with 0.3 ml of PBS in the control
group (n = 10). Five vaccinated and control ducks were
intravenously challenged with 106 EID50 of the SH441
virus in a volume of 100 μL at 3 weeks post-vaccination.H9N2 viruses
Virus isolation from oropharyngeal swabs (mean EID50/ml)
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were challenged with a same dose of virus via the
same route at 37 weeks post-vaccination. Oropharyn-
geal swabs were collected at 2 and 3 dpi for virus
detection by inoculating embryonated chicken eggs.
The collected allantoic fluids were passaged twice to
confirm the virus detection results.
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